DOSE Therapeutics, Inc. — Form D
DOSE Therapeutics, Inc. of DALLAS, TX, a company, filed a Form D exempt-offering notice with the SEC on 2022-05-12. The offering totals $10.0M, of which $10.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-05-12
- Form: D
- Accession: 0001927425-22-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $10.0M
- Amount sold: $10.0M
- Investors: 20
- Date of first sale: 2022-04-30
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-445465
Issuer
- Name: DOSE Therapeutics, Inc.
- CIK: 0001927425
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 3060 PEGASUS PARK, DALLAS, TX, 75247
- Phone: 682-428-0043
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Michael Bakes | Director | Dallas, TX |
| McHenry T Tichenor | Director | Dallas, TX |
| Steven L Mcknight | Director | Dallas, TX |
| Michael Bakes | Executive Officer | Dallas, TX |
| Blair Lapointe | Director | Dallas, TX |
| John Fulton Murray | Director | Dallas, TX |
| John Fulton Murray | Executive Officer | Dallas, TX |
| Deepak Fulton Nijhawan | Director | Dallas, TX |
Other filings by this issuer (1)
More